UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of Company as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices) | (Zip Code) |
Company’s
telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities Registered Pursuant to Section 12(b) of the Exchange Act:
Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On July 19, 2022, ProPhase Labs, Inc. (the “Company”) issued a press release announcing that it will hold a live webcast on Thursday, July 21, 2022 to review the latest developments at the Company and its subsidiaries. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information included in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
No. | Description | |
99.1 | Press Release dated July 19, 2022 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ProPhase Labs, Inc. | ||
By: | /s/ Monica Brady | |
Monica Brady | ||
Chief Accounting Officer |
Date: July 19, 2022
Exhibit 99.1
ProPhase Labs to Host Live Webcast to Discuss Business Developments on Thursday, July 21, 2022
Garden City, NY, July 19, 2022 (GLOBE NEWSWIRE) — ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced that it will host a live webcast on Thursday, July 21, 2022, at 11:30 a.m. EST / 8:30 a.m. PST. ProPhase Labs’ CEO and Chairman of the Board of Directors, Ted Karkus, will host the webcast and review the latest developments at ProPhase Labs and its subsidiaries.
To access the call, please use the following information:
Date: Thursday, July 21, 2022
Time: 11:30 a.m. Eastern time, 8:30 a.m. Pacific time
Participants can register for the webcast by navigating to: https://www.renmarkfinancial.com/events/prophase-labs-reviews-latest-developments-2022-07-21-113000
Pre-registration required fields of information include: name and email.
About ProPhase Labs
ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase”) is a diversified diagnostics and genomics company that seeks to leverage its CLIA lab services to provide whole genome sequencing and research direct to consumers and build a genomics data base to be used for further research. The Company continues to provide traditional CLIA molecular laboratory services, including COVID-19 testing.
ProPhase Diagnostics, Inc., a wholly-owned subsidiary of ProPhase, offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories including state-of-the-art polymerase chain reaction (PCR) testing for SARS-CoV-2 (COVID-19). Critical to COVID-19 testing, ProPhase Diagnostics provides fast turnaround times for results. ProPhase Diagnostics also offers best-in-class rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing. Announced plans for expansion of lab to include traditional clinical testing and genomics testing.
ProPhase Precision Medicine, Inc., a wholly-owned subsidiary of ProPhase, focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA. The data obtained from genomic testing can help to identify inherited disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression. Currently selling Nebula Genomics whole genome sequencing products direct-to-consumer online, with plans to sell in food, drug and mass (FDM) stores and to provide testing for universities conducting genomic research.
ProPhase BioPharma, Inc. (PBIO), a wholly-owned subsidiary of ProPhase, was formed for the licensing, development and commercialization of novel drugs and compounds beginning with Equivir and Equivir G.
ProPhase Labs has decades of experience researching, developing, manufacturing, distributing, marketing, and selling OTC consumer healthcare products and dietary supplements under the TK Supplements® brand and Phamaloz contract manufacturing subsidiary.
ProPhase Labs actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products.
For more information, visit www.ProPhaseLabs.com.
ProPhase Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
267-880-1111
investorrelations@prophaselabs.com
ProPhase Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman
514-939-3989
Jboidman@renmarkfinancial.com
-=*E
M($@FB]V3(_0US+,,*W;VB(]K#N='14-M=V]Y%YEM,DJ>J'-35UIIJZ- KS?Q
MB,>(I?=%/Z5Z17G7C08U\^\2_P!:\G.U_LWS7ZG/B?@-;P$/]&O3_MK_ "-=
M?7)> Q_H-V?^F@_E76UT99_ND/ZZLNC_ T%-=);>FI0J2N-DV.WH?Z?E79HBQHJ(H55& !T H=%D1D=0RL,$'H175/
M 0EA5AV]EOY]RW23AR'GWA'6$T^\:UG8+#<$88GA6[?G7H?6N(UGP9(KM-IF
M&0\F%C@CZ$]:H6FN:WH@$,T3M&O 2=#Q]#7GX7$U,"O8XF+Y5LUJ90FZ7NS6
MAZ-17$+XZNG^5-/1G]G)_3%*S^)M?&P1_8[9N#P4!'X\G\*[?[4HSTI)R?9)
M_F:>VB_AU.KMM2MKN[GMH'WM !O8= 3GC/X455T/1(M%MW19&DED(+N>,X]!
M17;1=1P3JJS-(WM[QJT445J4%%%% !1110 57OKI;*QFN7&1&A;'J>PJQ7->
M-+HQ:7%;K_RVDY^@Y_GBM*4.>:B9UI\D'(Y/2[*37=<5922'8R3,/3J?\*]!
MUF]72M%N+E0 8TP@Z<]!6-X)LA%82WA'SS-M'^Z/_KY_*JWQ#N2EA:6P/^MD
M+D?[H_\ KUV5'[;$*GT7],X(?N,-*KU?](\TF))))R3U-49:O2]*HRU[T#Y2
ML5VJ)JE:HFK0RB>I_"K6#-976DRN2T)\V('^Z>"!]#S^->BUX/X$U!M/\86)
M!PL[>0P]=W _7%>Z3W$-K'YD\J1)G&YV 'ZU\WF5-4ZSET>I]AE-;VF'L_LZ
M?Y$E%9,WB71X1\UZC?[@+?RJC+XVTM/N+/)]$Q_,UY$\;AX?%-?>>@ZD%NSI
M**Y"7QY"/]58R'W=P*I2>.[T_P"JM+=?]XEOZBN>6;82/VK^B9#KTUU.\HKS
MMO&VK-T%NOT0_P!34#^+M9?I<*O^[&*Q>=X9;7^[_@D_68'I=%>7-XFUENM_
M)^"J/Z5&=?U8]=0G_P"^JS>>T>D7^ OK4>QZK17DYUO5#_R_W'_?9H_MK4_^
M?^X_[[-3_;M+^1_@'UJ/8]8HKR<:WJ@_Y?[C_OLTX:]JPZ:A/_WU3_MVE_(_
MP#ZU'L>K45Y:OB36%Z7\GX@'^E3)XLUE.MT&_P!Z-?\ "J6>8?K%_A_F/ZS#
ML>EE5/50?PH Z "O.U\::LO7R&^L?\ ]>IX_'5^/]9;6S#_ &0P_J:T6E.LD%BKRJ
Cover |
Jul. 19, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jul. 19, 2022 |
Entity File Number | 000-21617 |
Entity Registrant Name | PROPHASE LABS, INC. |
Entity Central Index Key | 0000868278 |
Entity Tax Identification Number | 23-2577138 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 711 Stewart Avenue |
Entity Address, Address Line Two | Suite 200 |
Entity Address, City or Town | Garden City |
Entity Address, State or Province | NY |
Entity Address, Postal Zip Code | 11530 |
City Area Code | (215) |
Local Phone Number | 345-0919 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.0005 |
Trading Symbol | PRPH |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
-8?20$3;
M8T.P6BP^0"X99K>]9!:G
!6PA
M(AW2C:_#F$?K1KUF-4"!EY%.(Q]=[));)BU<7RFV)*AQI@AL-SG8/H\ES&[!
M%4>/VHPWPR8;7DU9BSW;W(^OILWM1>R:Y'VJCZ&/X:43L+_DTD"73,\AB6"G
M&@JCFX$TPK?:8-U32/D[-] $/:[J&O43P@4UTY,:>W(!4C*>+BP#MU7*'2?A.[[1WW/W5N-?"03.K&Q=:@O/
MS-8ET% #UZKVF2_06]QUY)%\P8^*RUN N5Z&^P6&*==S[ MG@2,%L#W QEBRK'9+GKN4'%)
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MUV1$7 \B8D-Z\A-O\0B8QI]1[\:2A[\8RIQ^G
Z;JU!]Q[:HMOW"_W
M+E9[Y']02P$"% ,4 " !L1/-4#8GCV$() !F-0 "@
M@ $ 97@Y.2TQ+FAT;5!+ 0(4 Q0 ( &Q$\U3-#N=GHA( #6; +
M " 6H) !F;W)M."UK+FAT;5!+ 0(4 Q0 ( &Q$\U0I
M$%Z(*@, +<+ 1 " 34< !P